Validation of blood testing for K-ras mutations in colorectal and pancreatic cancer

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2943-2947

  Rogosnitzky, Moshe ^a   Danks, Rachel ^b  

^a MedInsight Research Institute   (Israel)

^b MedInsight Research Institute   (United Kingdom)

Author keywords

Blood; Colorectal cancer; Diagnostic test; K ras; Pancreatic cancer; Plasma; Predictive test; Review; Serum

Indexed keywords

K RAS PROTEIN;

BLOOD EXAMINATION; CANCER TISSUE; COLORECTAL CANCER; GENE MUTATION; HUMAN; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SHORT SURVEY;

COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MUTATION; PANCREATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 77955825809     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (28)

1. Boyle P and Levin B: World Cancer Report 2008. Available at: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan= 1&codcol=76&codcch=26 [accessed 26 February 2010].
2. Grünewald K, Lyons J, Fröhlich A Feichtinger H, Weger RA, Schwab G, Janssen JW and Bartram CR: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43: 1037-1041, 1989. (Pubitemid 19158034)
3. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554, 1988.
4. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J and Bardelli A: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101: 1308-1324, 2009.
5. Garcia J, Riely GJ, Nafa K and Ladanyi M: KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Semin Diagn Pathol 25: 288-294, 2008.
6. Raponi M, Winkler H and Dracopoli NC: KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 8: 413-418, 2008.
7. Massarelli E, Varella-Garcia M, Tang X Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS and Wistuba II: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13: 2890-2896, 2007.
8. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S and Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286, 2005.
9. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD and Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
10. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S and Bardelli A: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648 (2007). (Pubitemid 46548951)
11. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F and Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
12. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F and Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
13. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R and Amado RG: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7: 184-190, 2008.
14. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
15. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P and Frebourg T: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169, 2007.
16. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E and Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515, 2008. (Pubitemid 351325672)
17. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F and Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145, 2007. (Pubitemid 47587019)
18. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA and Mauro DJ: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237, 2007. (Pubitemid 47325606)
19. Riely GJ and Ladanyi M: KRAS mutations: an old oncogene becomes a new predictive biomarker. J Mol Diagn 10: 493-495, 2008.
20. Mulcahy HE, Lyautey J, Lederrey C, Chen XQ, Lefort F, Vasioukhin V, Anker P, Alstead EM, Farthing MJ and Stroun M: Plasma DNA K-ras mutations in patients with gastrointestinal malignancies. Ann N Y Acad Sci 906: 25-28, 2000. (Pubitemid 30255453)
21. Lefebure B, Charbonnier F, Di Fiore F, Tuech JJ, Le Pessot F, Michot F, Michel P and Frebourg T: Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. Ann Surg 2009.
22. Trevisiol C, Di Fabio F, Nascimbeni R, Peloso L, Salbe C, Ferruzzi E, Salerni B and Gion M: Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. Int J Biol Markers 21: 223-228, 2006. (Pubitemid 46165213)
23. Ryan BM, Lefort F, McManus R, Daly J, Keeling PW, Weir DG and Kelleher D: A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow-up. Gut 52: 101-108, 2003. (Pubitemid 36020774)
24. Yen L, Yeh YS, Chen CW, Daly J, Keeling PW, Weir DG and Kelleher D: Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 15: 4508-4513, 2009.
25. Ryan BM, McManus RO, Daly JS, Keeling PW, Weir DG, Lefort F and Kelleher D: Serum mutant K-ras in the colorectal adenoma-to-carcinoma sequence. Implications for diagnosis, postoperative follow-up, and early detection of recurrent disease. Ann NY Acad Sci 906: 29-30, 2000.
26. Sorenson GD: A review of studies on the detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Ann NY Acad Sci 906: 13-16, 2000. (Pubitemid 30255450)
27. Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH and Laurent-Puig P: Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100: 542-548, 2002. (Pubitemid 34816154)
28. Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G and Raben D: Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformai radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol 32: 115-121, 2009.